logo-loader
HealthPharma & Biotech
Tissue Regenix Group PLC

Tissue Regenix boss to return to full-time duties in June

Steve Couldwell has been out of action so far this year while he undergoes medical treatment

Steve Couldwell
Despite Couldwell’s absence, TRX has “continued to develop in line with expectations”

The chief executive of Tissue Regenix Group PLC (LON:TRX) is to return to full-time duties next month.

At the end of last year, the regenerative medicines specialist confirmed Steve Couldwell would be taking a temporary leave of absence to undergo medical treatment.

READ: Tissue Regenix secures additional coverage for DermaPure from US GPO

“The board and I look forward to welcoming Steve back into the full time CEO position and are grateful for his ongoing commitment,” said chairman John Samuel, who held the fort whilst Couldwell was away.

“During his necessary absence Steve remained in daily contact with the business and continued to be integral to implementing the business strategy and establishing future business developments, along with the support of Gareth Jones who undertook the chief operating officer role during this period.”

Samuel added: “The business has continued to develop in line with the board expectations.”

Quick facts: Tissue Regenix Group PLC

Price: £0.03

Market: AIM
Market Cap: £39.26 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tissue Regenix "advancing on many fronts" says CEO after SurgiPure FDA clearance

Antony Odell, chief executive at Tissue Regenix (LON:TRX), talks to Proactive Investors about the US FDA clearance for SurgiPure XD, a skin graft for hernias derived from pig tissue. The group, which already has experience of commercialising products in the US, is planning a commercial...

on 03/09/2016

RNS

Unaudited Interim Results

1 week, 2 days ago

Appointment of CFO

3 weeks, 1 day ago

Directorate Change

on 08/01/2019

Holding(s) in Company

on 07/08/2019

Result of AGM

on 06/27/2019

Notice of AGM

on 06/04/2019

2 min read